Biogen 232SM303
99 years and younger
All genders
This study will evaluate HD nusinersen in participants previously treated with risdiplam who may not be receiving the optimal benefit from treatment because they have reached the dose ceiling of 5 mg.This Phase 3b, open-label, single-arm, interventional study will evaluate the efficacy and safety of HD nusinersen in nonambulatory participants …